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Objectives The study sought to determine whether rapid access to medical care and reperfusion results in a better progno-
sis in patients with in-hospital compared with out-of-hospital stent thrombosis (ST) in patients with ST-segment
elevation myocardial infarction (STEMI) in the HORIZONS-AMI (Harmonizing Outcomes with Revascularization
and Stents in Acute Myocardial Infarction) trial.
Background Whether the prognosis of in-hospital and out-of-hospital ST are similar is uncertain, with conflicting data reported
from prior studies.
Methods A total of 3,602 STEMI patients undergoing primary percutaneous coronary intervention (PCI) were randomized
to bivalirudin (n  1,800) versus unfractionated heparin (UFH) plus a glycoprotein IIb/IIIa inhibitor (GPI)
(UFHGPI; n  1,802). Stents were implanted in 3,202 patients, 156 (4.9%) of whom developed Academic Re-
search Consortium definite/probable ST during 3-year follow-up. We investigated the 1-year clinical outcomes
after ST in 54 patients with in-hospital ST compared with 102 patients with out-of-hospital ST.
Results One year after the ST event, patients with in-hospital compared with out-of-hospital ST had significantly greater
mortality (27.8% vs. 10.8%, p  0.01); most deaths in both groups occurred within 1 week of the ST event. Pa-
tients with in-hospital ST also had higher rates of major bleeding (21.2% vs. 6.0%, p  0.01), but a lower rate of
myocardial infarction (56.6% vs. 77.5%, p  0.01). Subgroup analysis within both in-hospital and out-of-hospital
ST groups indicated that subacute ST had the highest mortality. By multivariable analysis, 1-year mortality was
significantly increased in patients with in-hospital compared with out-of-hospital ST (adjusted hazard ratio: 4.62,
95% confidence interval: 1.98 to 10.77, p  0.01). Additional correlates of increased mortality after an ST event
included diabetes and randomization to UFHGPI (vs. bivalirudin).
Conclusions Following primary PCI for STEMI, more than one-third of all ST events during 3-year follow-up occurred during the
index hospital phase. Mortality and major bleeding were significantly higher after in-hospital ST compared with
out-of-hospital ST. (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction;
NCT00433966) (J Am Coll Cardiol 2012;59:1752–9) © 2012 by the American College of Cardiology
Foundation
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May 15, 2012:1752–9 In-Hospital Versus Out-of-Hospital Stent ThrombosisAlthough uncommon, stent thrombosis (ST) after percutane-
ous coronary intervention (PCI) is associated with high
rates of morbidity and mortality (1–4). Conceptually, the
prognosis following ST may depend on how rapidly reper-
fusion is restored. One might presume that out-of-hospital
ST would have a more dire prognosis than ST occurring
in-hospital due to the absence of readily available resusci-
tation or coronary angiography/PCI capabilities. However,
no systematic large series of ST has reported on the
potential differences in outcomes when an ST event occurs
during a hospitalization versus in an out-of-hospital setting.
See page 1760
We have previously reported that ST occurred in approxi-
mately 4% of patients during the 2-year follow-up after
primary PCI for ST-segment elevation myocardial infarction
(STEMI) in patients enrolled in the HORIZONS-AMI
(Harmonizing Outcomes with Revascularization and Stents in
Acute Myocardial Infarction) trial (5,6). In the present analy-
sis, we report the clinical outcomes after in-hospital
versus out-of-hospital ST from the HORIZONS-AMI
trial, including 3-year follow-up after the original index
STEMI and study enrollment.
Methods
The HORIZONS-AMI trial has been described in detail
previously (5,6). In brief, 3,602 patients admitted with
STEMI presenting within 12 h after symptom onset un-
dergoing a primary PCI management strategy were ran-
domized (1:1) to receive either bivalirudin monotherapy
plus bailout glycoprotein IIb/IIIa inhibitor [GPI]) or
nfractionated heparin (UFH) plus a GPI before PCI.
ollowing angiography, stents were implanted in 3,202
atients, including 3,006 who were randomized (3:1) to
AXUS Express2 paclitaxel-eluting stents or otherwise
dentical bare metal stents (Boston Scientific, Natick,
assachusetts). Clinical follow-up was performed at 30
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2011, accepted December 6, 2011.days, 6 months, 1 year, 2 years, and
3 years. The outcomes of patients
in whom ST developed during the
hospital period versus out-of-
hospital were compared.
Stent thrombosis was defined
according to the Academic Re-
search Consortium ST definite or
probable criteria (7), and all ST
events were adjudicated by an in-
dependent clinical events com-
mittee blinded to pharmacology
and stent assignment after review
of original source documenta-
tion. The HORIZONS-AMI
trial definitions for ischemic and bleeding events were used
throughout this study, as previously reported (8).
Statistical analysis. Categorical variables were compared
with Fisher’s exact test, and continuous variables with Student’s
t test. Starting from the time of the first ST event per patient,
time-to-event curves were derived using Kaplan-Meier meth-
ods. Landmark analyses were utilized to distinguish adverse
events occurring in 3 distinct time periods after the occurrence
of ST: 0 to 7 days, 7 to 30 days, and 30 days to 1 year.
Time-to-event data were compared using log-rank tests and
univariate Cox proportional hazards methods.
Logistic regression was used to identify the independent
predictors of in-hospital and out-of-hospital ST. Two
multivariable time-updated covariate-adjusted Cox propor-
tional hazards models were used to investigate the relative
impact of in- versus out-of-hospital ST on mortality. To
prevent over-fitting, the first model utilized a limited
number of covariates, and the second model used a propen-
sity score covariate. The following covariates were included
in the first model: diabetes mellitus, randomization to
treatment with UFH plus a GPI or bivalirudin, and current
smoking. These covariates were selected because of their
previously described clinical relationship to ST (9). Addi-
tionally, pre-procedural Thrombolysis In Myocardial In-
farction (TIMI) flow grade 0/1 (vs. 1), final post-
procedural TIMI flow grade 3 (vs. 3), peak creatine
phosphokinase, and protocol-defined non-coronary ar-
tery bypass graft surgery–related major bleeding were
added to the model because of the well-known relation-
ship with mortality after STEMI. The multivariable
model was built by stepwise variable selection with entry
and exit criteria set at the p  0.1 level. The propensity
score was estimated from a logistic regression model for
occurrence of in- or out-of-hospital ST. To calculate the
propensity score, the following variables were entered into the
model: baseline TIMI flow grade 1/0, final TIMI flow grade 3,
peak creatine phosphokinase, protocol-defined non-coronary ar-
tery bypass graft surgery–related major bleeding, pre-
randomization heparin, age, current smoking, randomization to
Abbreviations
and Acronyms
GPI  glycoprotein IIb/IIIa
inhibitor
PCI  percutaneous
coronary intervention
ST  stent thrombosis
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarction
UFH  unfractionated
heparinbivalirudin versus UFH plus a GPI, diabetes mellitus,
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score was added as the only covariate in addition to in-
versus out-of-hospital ST in the second multivariable Cox
model. Formal interaction tests were performed to deter-
mine whether diabetes or randomization to bivalirudin
versus UFHGPI affected the relative risk of mortality after
in-hospital versus out-of-hospital ST.
Results
Patients and baseline characteristics. Of 3,202 patients in
whom stents were implanted, definite/probable ST within 3
years occurred in 156 patients (4.9%). In-hospital ST
occurred in 54 patients (34.6%), and out-of-hospital ST
occurred in 102 patients (65.4%). The majority of ST events
in both groups were definite ST events (46 [85.2%] in-
hospital vs. 90 [88.2%] out-of-hospital; p  0.78). Five
patients had 2 ST events each, all of which were definite ST.
Two of these patients first had an in-hospital ST, followed
28 and 47 days later by an out-of hospital event; both of
these patients were included in the in-hospital ST group.
Three patients had 2 out-of-hospital ST events.
The median time to first ST was 1 day (interquartile
range: 0 to 5 days] in the in-hospital group and 360 days
(interquartile range: 100 to 604 days) in the out-of-hospital
group. Mean length of hospital stay was 8.67  6.63 days
versus 5.65  5.86 days in the in-hospital versus out-of-
hospital groups (p  0.01).
Baseline clinical and laboratory characteristics in the 2
groups are shown in Table 1. Patients with in-hospital
compared with out-of-hospital ST were less frequently
Baseline Characteristics of Patients From the OWith I -Hospit l and Out- -Hospital Definite/PrTable 1 B seline Characteris ics of Pa ientWith In-Hospital and Out-of-Hospita
Variable Description
Age, yrs
Male 6
Body mass index, kg/m2
History of hypertension 5
History of hyperlipidemia 4
Current smoking 5
History of diabetes mellitus 1
Insulin treated
History of prior myocardial infarction 1
History of prior percutaneous coronary intervention 1
History of prior coronary artery bypass grafting
History of congestive heart failure
History of peripheral vascular disease
History of renal insufficiency
Current dialysis
Creatinine clearance 60 ml/min 1
Anemia
Thrombocytopenia* 1
CPK at hospital admission, U/l
Peak CPK during original STEMI, U/l 2Values are median (interquartile range) or % (n/N). *Baseline platelet count
CPK  creatine phosphokinase; ST stent thrombosis; STEMI  ST-segmediabetic and current smokers, but more frequently had
thrombocytopenia. No significant differences were present
in other oral medical therapies prescribed before or during
the index hospitalization (data not shown), except for
beta-blocker use, which was less frequently used during the
index hospitalization in patients with in-hospital compared
with out-of-hospital ST (83.3% vs. 96.1%, respectively; p 
0.01). Angiographic and procedural characteristics during the
index STEMI treatment are summarized in Table 2. In
comparison with patients with out-of-hospital ST, those with
in-hospital ST more frequently had pre-PCI coronary TIMI
flow grade 0/1 and post-PCI coronary TIMI flow grade 3
were more likely to have been randomized to bivalirudin
monotherapy, and were less likely to have received pre-
randomization heparin. By multivariable analysis, baseline
TIMI flow grade 0/1, nonuse of pre-randomization heparin,
and randomization to bivalirudin were independent predictors
of in-hospital ST, whereas insulin-treated diabetes, prior PCI,
cigarette smoking, an elevated platelet count, and randomiza-
tion to heparin plus a GPI were independent predictors of
out-of-hospital ST (Table 3).
Clinical outcomes. As shown in Table 4, the 1-year rates
of mortality and major bleeding were higher in patients with
in-hospital compared with out-of-hospital definite or prob-
able ST, although the rates of reinfarction were lower. Most
of the differences in clinical outcomes (death, myocardial
infarction, and bleeding) appeared within 1 week of the ST
episode (Fig. 1). The results were similar when only definite
ST events were analyzed (Fig. 2); patients with in-hospital
compared with out-of-hospital definite ST had significantly
l Index Proceduree STm the Original Index Procedure
nite/Probable ST
ospital ST
n  54)
Out-of-Hospital ST
(n  102) p Value
50.5, 65.0) 59.0 (52.2, 67.4) 0.26
37/54) 80.4% (82/102) 0.10
24.8, 31.0) 27.4 (24.7, 29.8) 0.65
28/54) 58.8% (60/102) 0.40
25/54) 50.0% (51/102) 0.66
27/54) 66.3% (67/101) 0.047
6/54) 24.5% (25/102) 0.046
3/54) 13.7% (14/102) 0.12
7/54) 17.6% (18/102) 0.45
8/54) 21.6% (22/102) 0.31
1/54) 1.0% (1/102) 1.00
2/54) 5.9% (6/102) 0.72
2/54) 7.8% (8/102) 0.50
3/54) 4.9% (5/102) 1.00
1/54) 2.0% (2/102) 1.00
8/50) 16.3% (15/92) 0.96
4/53) 13.0% (12/92) 0.31
7/54) 3.0% (3/101) 0.03
87, 260) 154 (81, 330) 0.98
1,401, 4,501) 1,510 (540, 3,023) 0.005
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May 15, 2012:1752–9 In-Hospital Versus Out-of-Hospital Stent Thrombosishigher 1-year mortality (15.2% vs. 2.3%; p  0.01) and
major bleeding (23.5% vs. 6.7%; p  0.01), with lower rates
of MI (65.5% vs. 82.2%; p  0.03).
Angiographic and Procedural Variables From theof Patients With Subsequent In- and Out- f-HospTable 2 Angiog aphic and P ocedural Variabof Patients With Subsequent In- and
Variable Description
Door to balloon time, min
Symptom onset to balloon time, min 1
Left ventricular ejection fraction
Multivessel disease 5
Number of vessels treated
Number of lesions treated
Vessel treated
Left anterior descending coronary artery 3
Circumflex coronary artery 2
Right coronary artery 3
Number of stents implanted
Total stent length implanted
Post-stent dilation balloon used 3
Direct stenting 2
Any drug-eluting stent 7
Side-branch lesion treated
Aspiration catheter used
Pre-PCI TIMI flow grade 0/1 8
Final post-PCI TIMI flow grade 3 8
Post-PCI myocardial blush grade (dynamic)
Blush 0/1 3
Blush 2 2
Blush 3 4
Randomized to bivalirudin 6
Pre-randomization heparin 4
Pre-PCI clopidogrel loading dose given, any dose 9
600 mg clopidogrel loading dose 5
300 mg clopidogrel loading dose 4
Dissection
Thienopyridine prescribed at discharge 9
Aspirin prescribed at discharge 9
Aspirin and thienopyridine prescribed at discharge 9
Values are median (interquartile range), % (n/N), or mean  SD.
PCI  percutaneous coronary intervention; ST  stent thrombosis;
Multivariate Predictors of In-Hospital andOut-of-Hospital Definite/Probable Stent ThrombosisTable 3 Multivar ate Predictors of In-Hospital andOut-of-Hospital Definite/Probable Stent Thrombosis
Variable Odds Ratio p Value
In-hospital definite/probable ST
Bivalirudin (vs. UFHGPI) 1.88 (1.04–3.39) 0.04
Pre-procedural TIMI flow grade 0/1 versus
flow grade 2/3
6.36 (2.28–17.73) 0.0004
Pre-randomization heparin 0.46 (0.26–0.80) 0.006
Out-of-hospital definite/probable ST
Bivalirudin (vs. UFHGPI) 0.65 (0.43–0.98) 0.04
Insulin-treated diabetes 4.29 (2.36–7.80) 0.0001
Baseline platelet count (per 103 cells/mm3) 1.00 (1.00–1.01) 0.002
Prior PCI 2.52 (1.54–4.12) 0.0002
Current smoker 2.43 (1.58–3.73) 0.0001S
PCI  percutaneous coronary intervention; ST  stent thrombosis; TIMI  Thrombolysis In
yocardial Infarction; UFHGPI  unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor.Subgroup analysis indicated that within the in-hospital
ST group, mortality after acute ST was 7.1% and after
subacute ST was 50% (p  0.0004). Within the out-of-
ospital ST group, mortality was 27.6% after subacute
T, 3.3% after late ST, and 8.0% after very late ST (p 
.02). Detailed data on baseline clinical and angiographic
haracteristics as well as clinical outcome after acute,
ubacute, late, or very late ST are included in the Online
ppendix.
By multivariable analysis, in-hospital (compared with
ut-of-hospital) definite/probable ST was a powerful
ndependent predictor of mortality (Table 5). Diabetes
as also associated with increased mortality after an ST
vent, whereas randomization to bivalirudin (as opposed
o UFHGPI) was associated with improved survival
fter an ST event (Table 4, Fig. 4). Multivariate models
or in- versus out-of-hospital definite ST demonstrated
irectionally similar results to those for definite/probable
inal Index Procedureefinite/Probable STrom the O iginal Index Procedure
-of-Hospital Definite/Probable ST
ospital ST
 54)
Out-of-Hospital ST
(n  102) p Value
60.0–124.0) 93.0 (70.0–130.0) 0.50
161.0–273.5) 224.0 (163.0–375.0) 0.20
40–60) 50 (40–57) 0.93
31/54) 58.8% (60/102) 0.86
.1 0.3 1.0 0.1 0.16
.3 0.6 1.2 0.4 0.30
0.48
24/61) 37.1% (39/105)
13/61) 11.4% (12/105)
23/61) 50.5% (53/105)
.8 1.0 1.6 1.1 0.41
20.0–44.0) 24.0 (20.0–40.0) 0.47
21/53) 52.5% (52/99) 0.13
14/50) 39.0% (39/100) 0.18
37/52) 72.0% (72/100) 0.91
2/54) 6.9% (7/102) 0.72
5/54) 13.7% (14/102) 0.42
49/61) 64.8% (68/105) 0.03
51/61) 93.3% (98/105) 0.046
0.11
16/51) 18.6% (19/102)
14/51) 23.5% (24/102)
21/51) 57.8% (59/102)
35/54) 39.2% (40/102) 0.002
25/54) 64.7% (66/102) 0.03
51/54) 97.1% (99/102) 0.42
28/51) 58.6% (58/99) 0.52
23/51) 40.4% (40/99) 0.67
2/52) 2.0% (2/101) 0.61
39/40) 99.0% (101/102) 0.49
39/40) 98.0% (100/102) 0.66
38/40) 98.0% (100/102) 0.32
Thrombolysis In Myocardial Infarction.Origital Dles F
Out
In-H
(n
86.0 (
96.5 (
51 (
7.4% (
1
1
9.3% (
1.3% (
7.7% (
1
24.0 (
9.6% (
8.0% (
1.2% (
3.7% (
9.3% (
0.3% (
3.6% (
1.4% (
7.5% (
1.2% (
4.8% (
6.3% (
4.4% (
4.9% (
5.1% (
3.8% (
7.5% (
7.5% (
5.0% (T (Table 5).
thrombosis; TIMI Thrombolysis In Myocardial Infarction; UFHGPI unfractionated heparin plus
a glycoprotein IIb/IIIa inhibitor.
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With 156 ST events, the present study is 1 of the largest to
analyze the relationship between ST and subsequent mor-
tality. We observed that in patients with STEMI undergo-
ing primary PCI with stent implantation, more than one-
third of all ST events during the 3-year follow-up period
occurred during the hospital phase, shortly after the index
procedure. One-year mortality after ST was significantly
higher in patients with in-hospital compared with out-of-
hospital ST, despite more rapid access to care and similar
rates of target lesion revascularization. The occurrence of
in-hospital compared with out-of-hospital definite or prob-
able ST was an independent predictor of greater mortality
after multivariate adjustment, both with and without the use
of a propensity score. In-hospital compared with out-of-
hospital ST was also associated with greater rates of major
bleeding, but fewer myocardial infarctions.
In the present analysis, despite being distanced from
immediate clinical care, out-of-hospital ST was associated
with lower subsequent 1-year mortality than in-hospital ST.
Set at 7 Days and 30 Days
e/Probable Stent Thrombosis
T event.
 stent thrombosis.1-Year Clinical Outcomes in Patients WithIn-Hospital Versus Out-of-Hospital Definite/ProbableStent Thrombo is
Table 4
1-Year Clinical Outcom s in Patients With
In-Hospital Versus Out-of-Hospital Definite/Probable
Stent Thrombosis
Variable Description
In-Hospital ST
(n  54)
Out-of-Hospital
ST (n  102) p Value
Death 27.8% (15) 10.8% (11) 0.007
Cardiac 27.8% (15) 9.8% (10) 0.004
Noncardiac 0.0% (0) 1.1% (1) 0.51
Reinfarction 56.6% (30) 77.5% (79) 0.005
Q–wave 49.4% (26) 60.8% (62) 0.15
Non–Q–wave 11.9% (6) 20.9% (21) 0.17
Death or reinfarction 74.1% (40) 83.3% (85) 0.16
Stroke 7.6% (3) 2.0% (2) 0.16
Target vessel revascularization 83.3% (45) 80.4% (82) 0.47
Non–target vessel revascularization 23.5% (12) 21.0% (21) 0.69
Major bleeding (non–CABG related) 21.2% (10) 6.0% (6) 0.006
Major bleeding (including CABG
related)
23.2% (11) 7.0% (7) 0.005
Event rate percentages are Kaplan-Meier estimates (n).
CABG  coronary artery bypass grafting; PCI  percutaneous coronary intervention; ST  stentFigure 1 Time-to-Event Curves to 1-Year Follow-Up With Landmarks
of Clinical Outcome After In- Versus Out-of-Hospital Definit
Event rates during 0 to 7 days, 8 to 30 days, and 31 days to 1-year intervals after the S
C.I.  confidence interval; HR  hazard ratio; IH  in-hospital; OH  out-of-hospital; ST
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graphically confirmed definite ST was considered, which
eliminates any possible confounding by the inclusion of
unexplained deaths within probable ST as defined by the
Academic Research Consortium criteria. Thus, early ST
after primary PCI in STEMI may portend a particular poor
prognosis, presumably due to the incremental loss of myo-
cardium, than in patients with ST after an elective stent
procedure. These findings are consistent with a report by
Lasala et al., who studied 184 patients with ST after
paclitaxel-eluting stent implantation (10). Mortality was
higher after acute (29.4%) or subacute ST (41.7%) com-
pared with late (12%) or very late ST (13%). In contrast, the
RESTART (Registry of Stent Thrombosis for Review and
Reevaluation) investigators reported similar rates of 1-year
mortality in patients with acute or subacute ST (22.4%) and
late ST (23.5%), although mortality was less frequent in
patients with very late ST (10.5%) (2).
Major bleeding has been shown to be a powerful inde-
pendent predictor of subsequent mortality (11,12), and the
higher rates of major bleeding in patients with in-hospital
Figure 2 Time-to-Event Curves to 1-Year Follow-Up With Landm
30 Days of Clinical Outcome After In- Versus Out-of-H
Event rates during 0 to 7 days, 8 to 30 days, and 31 days to 1-year intervals aftecompared with out-of-hospital ST may have contributed tothe greater mortality of early ST. A recent subanalysis from
the HORIZONS-AMI study reported an unadjusted asso-
ciation between in-hospital major bleeding after STEMI
PCI and ST at 3-year follow-up (13). Indeed, occurrence of
major bleeding characterizes an overall high-risk patient
group. This reflects a population-based observation and
should not be construed as a statement implying a causal
relationship between bleeding and subsequent ST. In fact,
multivariate Cox proportional hazards analysis in the pres-
ent study did not find in-hospital stent thrombosis to be
related to a preceding bleeding event. The question of
whether bleeding causes ST, by triggering the coagulation
cascade and activating platelets, or whether treatment of ST
with femoral reinstrumentation, and antithrombotic and
antiplatelet therapy, leads to bleeding is difficult to answer.
Alternatively, it is not unthinkable that subclinical bleeding
may have led to platelet activation, precipitating ST, with
subsequent escalation of bleeding as a result of the treatment
for ST. Further study is required in order to answer this
question with confidence.
Conversely, it may be supposed that the lower rate of
Set at 7 Days and
al Definite Stent Thrombosis
T event. Abbreviations as in Figure 1.arks
ospit
r the Sreinfarction in patients with in-hospital ST would be
HR  hazard ratio; PCI  percutaneous coronary intervention; ST  stent thrombosis; TIMI 
Thrombolysis In Myocardial Infarction.
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pathophysiological mechanism may also be partly responsi-
ble for the differences of in-and out-of-hospital ST on
mortality. During the early phase, technical and procedural
factors are important predictors of ST (1,14,15), whereas
delayed neointimal coverage and ongoing vessel inflamma-
tion are associated with late ST (16).
Figure 3 1-Year Mortality According to
Academic Research Consortium Timing Definitions
ST  stent thrombosis.
ospital Stent Thrombosis According to
d the Presence or Absence of Diabetes Mellitus
ellitus. A borderline interaction was present between randomization arm and
bivalirudin; DM  diabetes mellitus; GPI  glycoprotein IIb/IIIa inhibitor;Adjusted Hazard Ratios for 1-Year MortalityFollowing In- Versus Out- f-Hospital StentThrombosis Adju ted for Selected Covaria es(M del 1) nd Propensi y Sc r (Model 2)
Table 5
Adjusted Hazard Ratios for 1-Year Mortality
Following In- Versus Out-of-Hospital Stent
Thrombosis Adjusted for Selected Covariates
(Model 1) and Propensity Score (Model 2)
HR (95% CI) p Value
Definite/probable ST
Multivariate model 1
In-hospital ST versus out-of-hospital ST 4.62 (1.98–10.77) 0.0004
Current smoking 0.44 (0.20–0.98) 0.04
Final post-PCI TIMI flow grade 3 0.27 (0.11–0.67) 0.004
Bivalirudin versus heparin plus GPI 0.13 (0.05–0.37) 0.0001
Multivariate model 2
In-hospital ST versus out-of-hospital ST 5.75 (2.37–13.97) 0.0001
Propensity score 0.04 (0.01–0.26) 0.001
Definite ST
Multivariate model 1
In-hospital ST versus out-of-hospital ST 40.02 (4.56–351.3) 0.0009
Peak CPK 1.37 (1.03–1.82) 0.0315
Diabetes mellitus 29.46 (2.80–309.4) 0.0048
Bivalirudin versus heparin plus GPI 0.02 (0.00–0.26) 0.0021
Multivariate model 2
In-hospital ST versus out-of-hospital ST 16.25 (2.83–93.29) 0.0001
Propensity score 0.03 (0.00–0.72) 0.004
CABG  coronary artery bypass grafting; CI  confidence interval; CK  creatine phosphokinase;Figure 4 Time-to-Event Curves for Mortality After In- Versus Out-of-H
Randomization to Bivalirudin Versus Heparin Plus a GPI an
(A) Bivalirudin versus heparin plus a GPI and (B) the presence or absence of diabetes m
ST type on subsequent mortality (pint  0.086) but not for diabetes (pint  0.56). BIV 
HEP  heparin; other abbreviations as in Table 1.
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May 15, 2012:1752–9 In-Hospital Versus Out-of-Hospital Stent ThrombosisIn the present study survival after ST was also worse in
patients with diabetes, whereas use of bivalirudin (as op-
posed to heparin plus a GPI) was associated with lower
mortality after ST. The favorable effect of bivalirudin was
principally present in patients with in-hospital ST, whereas
the effect of diabetes did not have any interaction with the
previous variables. Thus, despite the higher rate of acute ST
with bivalirudin compared with heparin plus a GPI in
STEMI patients undergoing primary PCI (7), the impact of
ST on mortality may be less severe when it occurs early after
bivalirudin. While the reason for this observation is un-
known (and the play of chance cannot be excluded), it may
be due to the reduced rate of major bleeding with bivaliru-
din compared to heparin plus GPI (especially because
bleeding complications were increased in patients with
in-hospital compared to out-of-hospital ST).
Study limitations. This study was a retrospective analysis
from a randomized trial and as such should be considered
exploratory. We did not have any information on antiplate-
let hyporesponsiveness or related genotypes. Intravascular
ultrasound imaging was scarce, not enabling evaluation of
the role of angiographically “silent” events such as stent
malapposition, underexpansion, or edge dissection. The fact
that the original stent implantation was performed during
STEMI may have contributed not only to the high rates of
early and late stent thrombosis, and may also have relatively
worsened the outcome of early versus late ST. Further
studies are required to determine whether an early in-
hospital ST event may be less catastrophic in patients
undergoing elective stent implantation. (Fig 3).
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